BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 10906625)

  • 1. Pharmacology of ACE inhibitors versus AT1 blockers.
    Vaughan D
    Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
    Feldman R
    Can J Cardiol; 2000 Aug; 16 Suppl E():41E-44E. PubMed ID: 10906626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The renin-angiotensin-aldosterone system and fibrinolysis.
    Felmeden DC; Lip GY
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):240-4. PubMed ID: 11881031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
    De Godoy MA; Rattan S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists.
    Meyer P; Flammer J; Lüscher TF
    Invest Ophthalmol Vis Sci; 1995 Mar; 36(3):555-62. PubMed ID: 7890486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC; MacDonald TM
    Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitor and AT1 antagonist stimulate duodenal HCO3- secretion mediated by a common pathway - involvement of PG, NO and bradykinin.
    Aihara E; Kagawa S; Hayashi M; Takeuchi K
    J Physiol Pharmacol; 2005 Sep; 56(3):391-406. PubMed ID: 16204762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.
    Davie AP; Rumley A; Lowe GD; McMurray JJ
    Thromb Haemost; 2001 Dec; 86(6):1585-6. PubMed ID: 11776334
    [No Abstract]   [Full Text] [Related]  

  • 16. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC; Hörl WH
    Wien Med Wochenschr; 2001; 151(7-8):160-4. PubMed ID: 11450164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renin-angiotensin-aldosterone system: focus on its distinct role in arterial hypertension and its various inhibitors as a therapeutic strategy to effectively lower blood pressure.
    Soldner A; Spahn-Langguth H; Mutschler E
    Pharmazie; 1996 Nov; 51(11):783-99. PubMed ID: 8985974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renin-angiotensin system and cardiovascular disease.
    Hollenberg NK
    Blood Press Suppl; 2000; 1():5-8. PubMed ID: 11059628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression.
    Schmeisser A; Soehnlein O; Illmer T; Lorenz HM; Eskafi S; Roerick O; Gabler C; Strasser R; Daniel WG; Garlichs CD
    Biochem Biophys Res Commun; 2004 Dec; 325(2):532-40. PubMed ID: 15530425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.